UA103154C2 - Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його - Google Patents

Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його

Info

Publication number
UA103154C2
UA103154C2 UAA200907944A UAA200907944A UA103154C2 UA 103154 C2 UA103154 C2 UA 103154C2 UA A200907944 A UAA200907944 A UA A200907944A UA A200907944 A UAA200907944 A UA A200907944A UA 103154 C2 UA103154 C2 UA 103154C2
Authority
UA
Ukraine
Prior art keywords
peptide
hla
amino acid
restricted
pharmaceutical composition
Prior art date
Application number
UAA200907944A
Other languages
English (en)
Russian (ru)
Inventor
Харуо Сугіяма
Original Assignee
Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк. filed Critical Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк.
Publication of UA103154C2 publication Critical patent/UA103154C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Винахід належить до пептиду, здатному зв'язуватися з молекулою HLA-A* 1101 і здатному індукувати цитотоксичний Т-лімфоцит (CTL), який складається з амінокислотної послідовності Thr Gly Val Lys Pro Phe Gin Cys Lys (SEQ ID NО:7), в якій від однієї амінокислоти до п'яти амінокислот можуть бути заміщені іншою (ими) амінокислотою (ами), а також до фармацевтичної композиції для лікування або профілактики злоякісного новоутворення, яка містить зазначений поліпептид, до способу індукції WT1-специфічного цитотоксичного Т-лімфоцита, набору, що містить зазначений поліпептид.
UAA200907944A 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його UA103154C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28
PCT/JP2007/074146 WO2008081701A1 (ja) 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
UA103154C2 true UA103154C2 (uk) 2013-09-25

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907944A UA103154C2 (uk) 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його

Country Status (28)

Country Link
US (4) US8653038B2 (uk)
EP (6) EP2980219B1 (uk)
JP (1) JP5484734B2 (uk)
KR (1) KR101525261B1 (uk)
CN (5) CN101573448B (uk)
AR (1) AR064555A1 (uk)
AU (1) AU2007340679B2 (uk)
BR (1) BRPI0720988A2 (uk)
CA (5) CA2886622A1 (uk)
CY (1) CY1116011T1 (uk)
DK (3) DK2341142T3 (uk)
ES (4) ES2556831T3 (uk)
HK (3) HK1159686A1 (uk)
IL (4) IL199052A0 (uk)
MX (1) MX2009007008A (uk)
MY (1) MY161664A (uk)
NO (1) NO20092774L (uk)
NZ (4) NZ592509A (uk)
PH (1) PH12014500902A1 (uk)
PL (1) PL2341142T3 (uk)
PT (1) PT2341142E (uk)
RU (1) RU2481398C2 (uk)
SG (1) SG177222A1 (uk)
SI (1) SI2341142T1 (uk)
TW (3) TWI554280B (uk)
UA (1) UA103154C2 (uk)
WO (1) WO2008081701A1 (uk)
ZA (1) ZA200903633B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540111T1 (de) 2003-11-05 2012-01-15 Int Inst Cancer Immunology Inc Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2591029T3 (es) 2006-04-10 2016-11-24 Sloan Kettering Institute For Cancer Research Péptidos WT-1 inmunogénicos y métodos para su uso
UA101608C2 (uk) 2007-02-27 2013-04-25 Интэрнэшнл Инститьют Оф Кэнсэр Иммунолоджы, Инк. Спосіб активації хелперних t-клітин
US10654892B2 (en) * 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
PE20141271A1 (es) * 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
AU2012309417B2 (en) 2011-09-14 2017-09-14 International Institute Of Cancer Immunology, Inc. Method for measuring anti-WT1 antibody
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
CN109324190A (zh) 2012-12-11 2019-02-12 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
MX2015007745A (es) 2012-12-17 2015-12-15 Otsuka Pharma Co Ltd Metodo para activar la celula t auxiliar.
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RU2687026C2 (ru) 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
RU2014102939A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для чрескожного введения
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2840941A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
KR20140099828A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
JP2014169280A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 経皮または粘膜投与用ワクチン組成物
WO2014157704A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
CA2907782C (en) * 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
CN114949171A (zh) * 2014-12-11 2022-08-30 株式会社癌免疫研究所 血管生成性疾病的免疫疗法
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
CA3043630A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
JP2023526723A (ja) 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
TW202200188A (zh) * 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
RU2237674C2 (ru) 1998-09-30 2004-10-10 Корикса Корпорейшн Композиции и способы wt1-специфичной иммунотерапии
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ATE399793T1 (de) * 1999-04-02 2008-07-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
ES2298353T3 (es) * 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
BR0311784A (pt) * 2002-06-14 2005-03-08 Merck & Co Inc Composto, composição farmacêutica, métodos de tratar ou prevenir o câncer, de modular a formação do fuso mitótico e de inibir a cinesina mitótica e processo para fabricar uma composição farmacêutica
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
DE602004023476D1 (de) 2003-01-15 2009-11-19 Chugai Pharmaceutical Co Ltd Dimerisiertes peptid
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Also Published As

Publication number Publication date
DK2479275T3 (en) 2015-12-14
CN102659924A (zh) 2012-09-12
NZ592509A (en) 2012-11-30
BRPI0720988A2 (pt) 2014-03-18
US8653038B2 (en) 2014-02-18
DK2341142T3 (en) 2014-12-08
ES2629578T3 (es) 2017-08-11
EP2341142A3 (en) 2011-09-07
MY161664A (en) 2017-04-28
JP5484734B2 (ja) 2014-05-07
EP2980219B1 (en) 2018-11-14
EP2098595A1 (en) 2009-09-09
US20110098233A1 (en) 2011-04-28
EP2980219A1 (en) 2016-02-03
EP3026115B1 (en) 2017-05-17
TW201345544A (zh) 2013-11-16
PT2341142E (pt) 2015-02-13
DK2479276T3 (en) 2015-12-21
NZ601175A (en) 2012-12-21
CA2886621A1 (en) 2008-07-10
TW200835513A (en) 2008-09-01
KR101525261B1 (ko) 2015-06-02
ES2554775T3 (es) 2015-12-23
HK1173187A1 (zh) 2013-05-10
CN101573448A (zh) 2009-11-04
CY1116011T1 (el) 2017-01-25
EP2098595A4 (en) 2010-03-17
EP2479275B1 (en) 2015-10-28
SG177222A1 (en) 2012-01-30
AU2007340679A1 (en) 2008-07-10
AU2007340679B2 (en) 2013-09-12
ES2556831T3 (es) 2016-01-20
PH12014500902B1 (en) 2016-01-11
CN102302788A (zh) 2012-01-04
RU2009128979A (ru) 2011-02-10
TWI599367B (zh) 2017-09-21
CN102335439B (zh) 2015-04-22
WO2008081701A1 (ja) 2008-07-10
IL215334A0 (en) 2011-11-30
AR064555A1 (es) 2009-04-08
JPWO2008081701A1 (ja) 2010-04-30
EP3026115A1 (en) 2016-06-01
TWI417103B (zh) 2013-12-01
EP2341142A2 (en) 2011-07-06
EP2341142B1 (en) 2014-11-26
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
US20140134200A1 (en) 2014-05-15
NZ592510A (en) 2012-11-30
CA2670658A1 (en) 2008-07-10
CN102335439A (zh) 2012-02-01
TW201630620A (zh) 2016-09-01
PH12014500902A1 (en) 2016-01-11
CN102659924B (zh) 2015-11-25
KR20090102772A (ko) 2009-09-30
RU2481398C2 (ru) 2013-05-10
MX2009007008A (es) 2009-07-10
CA2886622A1 (en) 2008-07-10
ES2526425T3 (es) 2015-01-12
EP2479275A1 (en) 2012-07-25
US20160199472A1 (en) 2016-07-14
NO20092774L (no) 2009-07-27
NZ577443A (en) 2011-12-22
CN102302788B (zh) 2016-06-15
HK1159686A1 (en) 2012-08-03
HK1221252A1 (zh) 2017-05-26
CN102295682A (zh) 2011-12-28
IL215333A0 (en) 2011-11-30
CN101573448B (zh) 2012-07-11
SI2341142T1 (sl) 2015-03-31
US9272026B2 (en) 2016-03-01
EP2479276A1 (en) 2012-07-25
IL215332A0 (en) 2011-11-30
PL2341142T3 (pl) 2015-04-30
IL199052A0 (en) 2010-03-28
ZA200903633B (en) 2010-02-24
CA2886619A1 (en) 2008-07-10
TWI554280B (zh) 2016-10-21
US20180064795A1 (en) 2018-03-08
CA2886620A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
MXPA06001283A (es) Derivados de insulina novedosos.
CY1113117T1 (el) Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
WO2006087550A3 (en) Amyloid-binding peptides, analogues and uses thereof
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
BRPI0718996B8 (pt) método para a preparação de um peptídio da fórmula h-d-?-nal-[cys-tyr-d-trp-lys-val-cys]-thr-nh2 ou h-d-?-nal-cys(acm)-tyr-d-trp-lys-val-cys(acm)-thr
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
EP2039367A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
MX2020010520A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas.
WO2010011994A3 (en) Polypeptides and uses thereof
WO2006097748A3 (en) Peptide stabilizer compounds and screening method
MY126118A (en) Somatostatin analogs for the treatment of cancer
EP3771719A8 (en) A peptide binding to tau-protein
EP1915617A4 (en) METHOD AND COMPOSITIONS FOR IDENTIFYING A PEPTIDE WITH INTERMOLECULAR INTERACTION WITH AN INTERESTING OBJECTIVE
EP1730174A4 (en) PEPTIDE CARRIER FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
DE60018937D1 (de) Somatostatin analoge und deren verwendung zur behandlung von krebs
AU2003296543A8 (en) Peptides having a high cysteine content